Standard BioTools downgraded to Sector Weight from Overweight at KeyBanc

KeyBanc analyst Paul Knight downgraded Standard BioTools (LAB) to Sector Weight from Overweight without a price target The company reported preannounced Q4 results with “disappointing” initial 2025 revenue guidance, the analyst tells investors in a research note. The firm says Standard Bio attributed its guidance to the proposed White House National Institutes of Health spending cut that may drive cautious spending for its academic customers. With a “tepid” spending environment and more meaningful commercial revenue from Illumina unlikely to occur until 2026, KeyBanc downgrades the shares.